DUBLIN, Oct. 28, 2020 /PRNewswire/ — The “T-Cell Immunotherapy Market Research Report by Mechanism Of Action, by Product Class – Global Forecast to 2025 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global T-Cell Immunotherapy Market is expected to grow from USD 37,168.68 Million in 2019 to USD 76,066.68 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 12.67%. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global T-Cell Immunotherapy Market including Adaptimmune Therapeutics, Autolus, Bluebird Bio, CARsgen Therapeutics, Celgene, Cellectis, Innovative Cellular Therapeutics, Novartis, and Sinobioway Cell Therapy. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the T-Cell Immunotherapy Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between
(RTTNews) – Eli Lilly and Co. (LLY) announced Wednesday an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg for $375 million in an effort to fight COVID-19. Bamlanivimab is a potent, neutralizing IgG1 monoclonal antibody or mAb directed against the spike protein of SARS-CoV-2. Lilly in early October submitted a request for an Emergency Use Authorization or EUA for bamlanivimab to the FDA for the treatment of mild to moderate COVID-19 in high-risk patients. If FDA grants an EUA, the U.S. government will accept the vials of bamlanivimab, which will be delivered over the two months following an EUA. The agreement also provides the option for the U.S. government to purchase up to an additional 650,000 vials through June 30, 2021, under the same terms. Lilly has successfully completed a Phase 1 study of bamlanivimab in hospitalized patients with COVID-19 (NCT04411628). A Phase 2 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) is ongoing. Further, a Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing. Bamlanivimab is also is being tested in the National
DUBLIN, Oct. 28, 2020 /PRNewswire/ — The “Specialty Fats & Oils Market by Type (Specialty Fats & Specialty Oils), Application (Chocolate & Confectionery, Bakery Product, Processed Food, Animal Nutrition, Dairy Product, and Infant Nutrition), Form (Dry &…
DALLAS, Oct. 28, 2020 /PRNewswire/ — Santander Consumer USA Holdings Inc. (NYSE: SC) (“SC” or the “Company”) today announced net income for the third quarter ended September 30, 2020 (“Q3 2020”) of
NORWICH, England, Oct. 28, 2020 /PRNewswire/ — BizClik Media announced today the launch of the November issue of Construction Global magazine.This month's magazine has a strong environmental thread running…
GOTHENBURG, Sweden, Oct. 28, 2020 /PRNewswire/ — SKF welcomes institutional investors, financial analysts and financial media to the Group's first virtual Capital Markets Day on 4 November at 13:00-16:00 (CET). To participate, please register at: https://skf.
SAN FRANCISCO, Oct. 28, 2020 /PRNewswire/ — The global coconut water market size is expected to reach USD 14.06 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 16.1% from 2020 to 2027. The rising adoption of healthy and natural drinks among all age groups across the globe is crucial for market growth. Moreover, several health benefits associated with the product are propelling the demand for the product as a nutritional drink among consumers. Key suggestions from the report: By packaging, the tetra pack segment accounted for the largest revenue share of more than 40.0% in 2019. Such packaging formats are expected to gain popularity among consumers as they offer a long life to the liquid packaged inside The liquid form segment held the largest share of more than 80.0% in 2019. Most manufacturers in the industry offer the product in the liquid form as these products are ready for consumption and can be consumed on the go The online distribution channel segment is expected to register the fastest CAGR of 17.0% from 2020 to 2027. The online channel has emerged as the new preferred channel for shopping among generation Y, Z, and Alpha
(RTTNews) – German telecom company Telefonica Deutschland Holding AG (TELDF.OB, TFTHF.OB) reported Wednesday that its third-quarter net profit was 390 million euros, compared to last year’s loss of 24 million euros. Basic earnings per share were 0.13 euro, compared to loss of 0.01 euro a year ago. OIBDA amounted to 976 million euros, up 65.8 percent from last year. Adjusted OIBDA was 595 million euros, a growth of 0.8 percent. OIBDA margin grew to 52.1 percent from 31.6 percent last year. Adjusted OIBDA margin slightly improved to 31.8 percent from 31.7 percent a year ago. Revenues edged up 0.4 percent to 1.873 billion euros from 1.865 billion euros last year on sustained MSR and fixed revenue trends. Mobile revenues dropped 0.4 percent, while Mobile service revenue was flat. Looking ahead, the company continues to expect fiscal 2020 revenue to be flat to slightly positive and adjusted OIBDA to be broadly stable to slightly positive. The company’s 5G network went live on October 3 and is already operational in the first 15 German cities. The company is driving its 5G rollout over the coming months to reach >30 percent of population coverage by YE21, ~50 percent by YE22 and close to